The role of Anti-MCV in early rheumatoid arthritis diagnosis
Discover how Anti-MCV helps identify rheumatoid arthritis earlier, especially in patients who test negative for conventional biomarkers, enabling faster treatment and better outcomes.
Discover how Anti-MCV helps identify rheumatoid arthritis earlier, especially in patients who test negative for conventional biomarkers, enabling faster treatment and better outcomes.
Learn how collaboration between researchers, clinicians, and diagnostic companies transformed Anti-MCV into a globally adopted biomarker, and the key challenges of bringing innovation to routine care.
Explore how advanced biomarkers, earlier detection, risk prediction, and personalized therapies are shaping the next generation of autoimmune disease management and improving patient care.
The earlier you diagnose a patient, the earlier you can intervene therapeutically
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.